Eagle Health to offer ‘health shake’ to China’s over 100 million diabetes sufferers

Eagle Health Holdings Chinese diabetes market

Eagle Health Holdings (ASX: EHH) has signed a licensing agreement with Omni Innovation Pty Ltd to exclusively manufacture, market and distribute Omni’s clinically proven pre-meal shake product for Type 2 diabetes and Pre-­Type 2 diabetes throughout mainland China.

The announcement is part of Eagle Health’s strategy to leverage efficacious, clean green Australian ingredients and brands into the China market.

The diabetes market focused product will be distributed through Eagle Health’s extensive network of pharmacies, online and other retail outlets.

Eagle Health estimates that in 2018 there will be over 120 million men and women in China suffering from Type 2 diabetes growing to over 160 million by 2030.

An ageing and growing population and increasing obesity are the main drivers of this alarming trend that is particularly prevalent in urban Chinese locations.

Eagle Health EHH China diabetes Omni Innovation
Arie Nudel Managing Director Omni Innovation, Ian Brown Chairman Omni Innovation, Zhang Ming Wang CEO Eagle Health Holdings Ltd, Professor Michael Horowitz Professor of Medicine & Head Endocrine Unit Adelaide Medical School and Rodney Hannington Executive Director Eagle Health Holding Ltd at the signing of the Licensing Agreement.

Eagle Health’s strong pharmacy and supermarket distribution footprint in urban China means that the company is well positioned to help Type 2 diabetes sufferers make the necessary lifestyle and diet changes with the support of their Healthcare Professional and the product.

Mr Zhang Mingwang, Managing Director of Eagle Health, said:

“We are honoured to be able to provide Type 2 diabetes sufferers in China such a world class and clinically validated solution to support them in their lifestyle intervention in order to manage this serious national health issue.

We know that Chinese consumers and their Healthcare practitioners will recognise Omni’s clinical efficacy and the high quality product developed in Australia and now produced by the trusted Eagle Health Brand.

The product will be sold in Pharmacies, online and supermarkets in China at an affordable price to ensure maximum reach of sufferers.”

Eagle Health Holdings Omni Innovation China diabetes agreement signing
Signing of the licensing agreement between Eagle Health Holdings and Omni Innovation.

Filip has written in both Australia and abroad during his career, covering everything from the global economy, politics and geopolitical issues to commodities and small cap stocks on the ASX.